Literature DB >> 34889423

Immunology 101: fundamental immunology for the practicing hematologist.

Shannon A Carty1.   

Abstract

From an evolutionary perspective, the immune system developed primarily to protect the host from pathogens. In the continuous balance between killing pathogens and protecting host tissues, selective pressures have shaped the discriminatory functions of the immune system. In addition to protection against microbial pathogens, the immune system also plays a critical role in antitumor immunity. Immune dysfunction, either under- or overactivity, is found in a wide range of hematologic disorders. Here we review the fundamental features of the immune system and the key concepts critical to understanding the impact of immune dysfunction on hematologic disorders.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 34889423      PMCID: PMC8791153          DOI: 10.1182/hematology.2021000260

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  42 in total

1.  A complete immunoglobulin gene is created by somatic recombination.

Authors:  C Brack; M Hirama; R Lenhard-Schuller; S Tonegawa
Journal:  Cell       Date:  1978-09       Impact factor: 41.582

Review 2.  Checkpoints that control B cell development.

Authors:  Fritz Melchers
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

Review 3.  Understanding Subset Diversity in T Cell Memory.

Authors:  Stephen C Jameson; David Masopust
Journal:  Immunity       Date:  2018-02-20       Impact factor: 31.745

4.  PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Authors:  Benjamin J Chen; Bjoern Chapuy; Jing Ouyang; Heather H Sun; Margaretha G M Roemer; Mina L Xu; Hongbo Yu; Christopher D M Fletcher; Gordon J Freeman; Margaret A Shipp; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2013-05-14       Impact factor: 12.531

Review 5.  Molecular mechanisms of T cell co-stimulation and co-inhibition.

Authors:  Lieping Chen; Dallas B Flies
Journal:  Nat Rev Immunol       Date:  2013-03-08       Impact factor: 53.106

6.  GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.

Authors:  Tianjiao Wang; Andrew L Feldman; David A Wada; Ye Lu; Avery Polk; Robert Briski; Kay Ristow; Thomas M Habermann; Dafydd Thomas; Steven C Ziesmer; Linda E Wellik; Thomas M Lanigan; Thomas E Witzig; Mark R Pittelkow; Nathanael G Bailey; Alexandra C Hristov; Megan S Lim; Stephen M Ansell; Ryan A Wilcox
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

7.  Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.

Authors:  Stephen M Ansell; Michael B Maris; Alexander M Lesokhin; Robert W Chen; Ian W Flinn; Ahmed Sawas; Mark D Minden; Diego Villa; Mary-Elizabeth M Percival; Anjali S Advani; James M Foran; Steven M Horwitz; Matthew G Mei; Jasmine Zain; Kerry J Savage; Christiane Querfeld; Oleg E Akilov; Lisa D S Johnson; Tina Catalano; Penka S Petrova; Robert A Uger; Eric L Sievers; Anca Milea; Kathleen Roberge; Yaping Shou; Owen A O'Connor
Journal:  Clin Cancer Res       Date:  2021-01-15       Impact factor: 12.531

Review 8.  Primary Immunodeficiency and Cancer in Children; A Review of the Literature.

Authors:  Rejin Kebudi; Ayca Kiykim; Merve K Sahin
Journal:  Curr Pediatr Rev       Date:  2019

9.  Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.

Authors:  Philippe Armand; Scott Rodig; Vladimir Melnichenko; Catherine Thieblemont; Kamal Bouabdallah; Gayane Tumyan; Muhit Özcan; Sergio Portino; Laura Fogliatto; Maria D Caballero; Jan Walewski; Zafer Gulbas; Vincent Ribrag; Beth Christian; Guilherme Fleury Perini; Gilles Salles; Jakub Svoboda; Jasmine Zain; Sanjay Patel; Pei-Hsuan Chen; Azra H Ligon; Jing Ouyang; Donna Neuberg; Robert Redd; Arkendu Chatterjee; Arun Balakumaran; Robert Orlowski; Margaret Shipp; Pier Luigi Zinzani
Journal:  J Clin Oncol       Date:  2019-10-14       Impact factor: 44.544

10.  CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.

Authors:  Xiaojuan Liu; Yang Pu; Kyle Cron; Liufu Deng; Justin Kline; William A Frazier; Hairong Xu; Hua Peng; Yang-Xin Fu; Meng Michelle Xu
Journal:  Nat Med       Date:  2015-08-31       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.